Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIHEP 3: Triheptanoin in Huntington's disease
2014-005112-42Phase 2Completed
- Sponsor
- Inserm
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of triheptanoin in Huntington disease (HD) (2 arms), sponsored by Inserm. Primary endpoint: Primary: Index of brain energy restoration (Pi/PCr difference during visual stimulation vs rest/recovery) by 31P-MRS at 3 months. Started Jun 2015; status: completed.
02
Drugs
triheptanoin
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2014-005112-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005112-42.